-
Highlighting Mental Health Disparities in Indigenous Communities Affected by Huntington’s Disease
Latest News
-
Encouraging news from Skyhawk, as SKY-0515 Phase 1/2 data continues to hold promise
Skyhawk shared data at the 15 month mark for SKY-0515 treatment in people with HD in their Phase 1/2 trial. The drug is working as designed and there are some encouraging signs that it could be helpful for some symptoms of HD.
-
Food for Thought: The Importance of Nutrition in Huntington’s Disease
⏱️8 min read | What if nutrition is one of the warning lights we should be checking earlier in Huntington’s disease? New research suggests simple nutrition measures may help identify when people with HD need extra support.
-
Could Brain Waves Help Track Huntington’s Disease?
⏱️7 min read | A review of 23 studies found that EEG changes were linked to disease progression and clinical measures in HD. While more research is needed, EEG holds potential to become a simple, non-invasive biomarker for monitoring HD over time.
-
Hot techniques in HD research
⏱️11 min read | Five HD scientists discuss the cutting-edge techniques driving their work. These technical innovations will provide biological insights and move us closer to treatments.
-
Keeping an Eye on HD: Can Visual Thinking Skills Help Track Disease Progression?
⏱️8 min read | What if Huntington’s disease changes how we “see” the world before we even notice symptoms? New research suggests visual thinking skills may help track HD progression over time.
-
August 2026: This month in Huntington’s disease research
August was another busy month for HD research! Learnings from past trials, new approaches to huntingtin lowering, the start of INSIGHTT and PRECISE-HD, three packed days at HD2026, and the HDBuzz Prize: we’ve got you covered.
-
First participant dosed in the PRECISE-HD trial of pridopidine
The first participant has now been dosed in the Phase 3 PRECISE-HD trial of pridopidine for HD. The study will test whether the drug can slow disease progression in people most likely to benefit
-
Taking A Short Cut: New Routes to Huntingtin-Lowering Therapies
⏱️5 min read | New research points to HTT1a, a toxic shortened form of huntingtin, as a key driver of disease and a promising therapeutic target in HD.
-
A shot in the arm for HTT lowering: INSIGHTT trial begins testing SRP-1005
A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, but this approach could add an important new arrow to the HD drug development quiver.
-
The 2026 HDBuzz Prize for Young Science Writers Is Open!
⏱️ 5 min read | Announcing the 2026 HDBuzz Prize for Young Science Writers – sponsored by the Huntington’s Disease Foundation!
HDBuzz Trial Tracker
Show 10 more Show less
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
